Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Rating of "Buy" by Analysts

Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD - Get Free Report) have been assigned an average recommendation of "Buy" from the six research firms that are currently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $5.33.

A number of research firms recently weighed in on CLSD. HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research report on Thursday, November 14th. Chardan Capital reissued a "buy" rating and issued a $6.00 price objective on shares of Clearside Biomedical in a research note on Friday, November 15th. StockNews.com raised Clearside Biomedical from a "sell" rating to a "hold" rating in a research report on Saturday, November 16th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $6.00 price target on shares of Clearside Biomedical in a research note on Wednesday, November 13th.

Insider Buying and Selling at Clearside Biomedical

In other Clearside Biomedical news, insider Ngai Hang Victor Chong bought 36,500 shares of Clearside Biomedical stock in a transaction dated Friday, November 1st. The stock was bought at an average cost of $1.00 per share, for a total transaction of $36,500.00. Following the purchase, the insider now owns 100,000 shares of the company's stock, valued at $100,000. The trade was a 57.48 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 9.20% of the company's stock.

Institutional Investors Weigh In On Clearside Biomedical

A number of institutional investors have recently made changes to their positions in CLSD. SG Americas Securities LLC bought a new position in shares of Clearside Biomedical in the first quarter valued at approximately $49,000. XTX Topco Ltd grew its holdings in Clearside Biomedical by 172.2% during the second quarter. XTX Topco Ltd now owns 54,313 shares of the company's stock valued at $71,000 after purchasing an additional 34,359 shares during the period. Renaissance Technologies LLC grew its holdings in Clearside Biomedical by 6.6% during the second quarter. Renaissance Technologies LLC now owns 582,689 shares of the company's stock valued at $757,000 after purchasing an additional 35,900 shares during the period. Geode Capital Management LLC grew its holdings in Clearside Biomedical by 8.8% during the third quarter. Geode Capital Management LLC now owns 731,386 shares of the company's stock valued at $929,000 after purchasing an additional 59,089 shares during the period. Finally, Johnson & Johnson bought a new position in Clearside Biomedical during the third quarter valued at $105,000. Institutional investors own 18.75% of the company's stock.

Clearside Biomedical Price Performance

Shares of CLSD traded up $0.04 during trading hours on Friday, reaching $1.06. 235,171 shares of the company's stock traded hands, compared to its average volume of 397,994. The firm has a market capitalization of $80.39 million, a price-to-earnings ratio of -2.31 and a beta of 2.33. Clearside Biomedical has a twelve month low of $0.92 and a twelve month high of $2.12. The business's fifty day simple moving average is $1.18 and its two-hundred day simple moving average is $1.18.

Clearside Biomedical (NASDAQ:CLSD - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.04. The firm had revenue of $1.04 million for the quarter, compared to analyst estimates of $0.25 million. During the same period in the previous year, the firm earned ($0.15) earnings per share. On average, equities research analysts expect that Clearside Biomedical will post -0.48 EPS for the current year.

About Clearside Biomedical

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.